A Phase II Trial of Autologous Stem Cell Transplant Followed by Miniallogeneic Stem Cell Transplant in Lieu of Standard Allogeneic Bone Marrow Transplantation for Treatment of Multiple Myeloma

II

To determine the effectiveness of receiving an allogeneic transplant after an autologous transplant to treat myeloma

• Diagnosis of myeloma
• 18 to 70 years old
• No previous autologous or allogeneic transplant
• adequate heart, liver, kidney function
• No nonsecretory myeloma
• HLA-matched sibling is needed

Patients receive an IV injection of melphalan the day before receiving an autologous stem cell transplant. The day after the stem cells have been harvested and reinfused, patients receive G-CSF, either by injection or IV until white blood cell counts have recovered and are stable for 3 days. Approximately 100 to 182 days after patient's own stem cells are reinfused, the miniallogeneic procedure begins including fludarabine and cyclophosphamide over 5 days followed by and donor stem cell infusion. A combination of cyclosporine and solumedrol are administered for up to 4 months after the miniallogeneic transplant to help with acceptance of the new cells and to help prevent graft vs host disease

Florida
H Lee Moffitt Cancer Center
Melissa Alsina, MD
AlsinaM@moffitt.usf.edu
813-903-6886